News Search Results
May 12, 2026, 14:19 ET Binaytara's 2026 National Summit on Hematologic Cancers Reinvents the Medical Conference -- and Invests $250,000 Behind the Next Generation of Researchers
rebuilt to change that. At its core is the "Gray Zone" format: case-based sessions in which two to three real-world hematology cases — in leukemia, lymphoma, multiple myeloma, MPN/CML, and CLL — unfold in clinical layers, with expert panelists engaging in open, unscripted deliberation. Moderators are explicitly
More news about: Binaytara
May 12, 2026, 12:02 ET Wisner Baum Investigates Syngenta Amid Renewed Questions Over Atrazine Safety
Esfandiary said. "As more research emerges linking atrazine to non-Hodgkin lymphoma, families deserve answers about whether these risks were known and adequately disclosed."Investigation Focused on Non-Hodgkin Lymphoma ClaimsWisner Baum's investigation is focused on individuals who
More news about: Wisner Baum
May 11, 2026, 07:51 ET ProBio and Curocell Achieve Key CAR-T Milestone with BLA Regulatory Approval and Commercial Readiness
code: CRC01). This next-generation CD19-targeted CAR-T cell therapy is developed for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This approval not only highlights Korea's growing innovation in advanced therapies but also marks a critical step towards bringing transformative
More news about: ProBio Inc.
May 08, 2026, 07:30 ET Soligenix Announces Recent Updates and First Quarter 2026 Financial Results
Officer of Soligenix. "Despite the fact that HyBryte™ (synthetic hypericin) demonstrated statistically significant reductions in cutaneous T-cell lymphoma (CTCL) lesions after 6 weeks treatment in the first FLASH study, a similar signal was not observed with 18 weeks of treatment in this study. Over
More news about: SOLIGENIX, INC.
May 07, 2026, 08:00 ET Pierre Fabre Pharmaceuticals Announces Regulatory Update Following Type A Meeting with U.S. Food and Drug Administration (FDA) on Tabelecleucel Biologic License Application (BLA)
Executive Officer of PFP, the Pierre Fabre Laboratories pharmaceutical subsidiary in the United States. "U.S. patients living with this ultra-rare form of lymphoma urgently need an FDA-approved treatment option as none currently exist, and the lifespan of individuals with R/R EBV+ PTLD is often measured in weeks
More news about: Pierre Fabre Pharmaceuticals
May 06, 2026, 11:34 ET BioOra Limited and Wellington Zhaotai Therapies Limited (WZTL) sign Heads of Terms to Advance their global expansion of CAR T-Cell Therapy
partnership, BioOra and the Malaghan Institute are now confirming the safety and efficacy of Atla-cel in patients with relapsed/refractory large B-cell lymphoma in a pivotal Phase 2 study designed to enable registration in New Zealand and Australia (ENABLE-2,
More news about: BioOra
May 06, 2026, 08:17 ET VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats
findings for canine lymphoma3-5, this study aimed to highlight the utility of circulating nucleosomes as biomarker to differentiate healthy vs intermediate-large cell lymphoma in cats."Nucleosome levels were significantly higher in cats with intermediate-large cell lymphoma compared to healthy
More news about: VolitionRx Limited
May 05, 2026, 20:00 ET Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization
diftitox-cxdl), approved by the Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy, and has also entered into a definitive agreement for the immediate exercise of certain outstanding
More news about: Citius Oncology, Inc.
May 05, 2026, 17:11 ET Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026
inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor, ibrutinib, in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in the TakeAim CLL Phase 2 study (CA-4948-203) of
More news about: Curis, Inc.
May 05, 2026, 11:00 ET Roundup Settlement Outreach Teams Going Door to Door Across California's Farming Communities
diagnosed with non-Hodgkin lymphoma could receive $6,000 to $165,000 or more in compensation, depending on their type of exposure, their diagnosis, and age at diagnosis.Even if you feel healthy today, this settlement may affect your legal rights. Non-Hodgkin lymphoma can take 10 to 15 years
More news about: Holland Law Firm
May 05, 2026, 08:05 ET AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
immune system problems. RINVOQ may increase your risk of certain cancers. Lymphoma and other cancers, including skin cancers, can happen. Current or past smokers are at higher risk of certain cancers, including lymphoma and lung cancer. Follow your HCP's advice about having your skin checked for skin
More news about: AbbVie
May 05, 2026, 08:00 ET Roundup Settlement Outreach Launches in New York City and Long Island to Reach Landscapers and Outdoor Workers
diagnosed with non-Hodgkin lymphoma could receive $6,000 to $165,000 or more in compensation, depending on their type of exposure, their diagnosis, and age at diagnosis.Even if you feel healthy today, this settlement may affect your legal rights. Non-Hodgkin lymphoma can take 10 to 15 years
More news about: Holland Law Firm
May 05, 2026, 08:00 ET Roundup Settlement Outreach Reaches Landscapers and Outdoor Workers Across Philadelphia, Bucks County, and the Lehigh Valley
diagnosed with non-Hodgkin lymphoma could receive $6,000 to $165,000 or more in compensation, depending on their type of exposure, their diagnosis, and age at diagnosis.Even if you feel healthy today, this settlement may affect your legal rights. Non-Hodgkin lymphoma can take 10 to 15 years
More news about: Holland Law Firm
May 05, 2026, 06:00 ET Billboard and Scoreboard Manufacturer Formetco Hits $1M Milestone Raised to Support Local Charities
initiatives.Organizations that have benefited from events hosted at the facility include Rainbow Village, Young Life, Make-A-Wish Foundation, the Leukemia & Lymphoma Society, the Rotary Club of Gwinnett County, and local high school booster programs—all contributing to meaningful impact across Gwinnett County.
More news about: Formetco, LLC
May 04, 2026, 07:30 ET ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
Comprehensive Cancer Center-led multi-center trials of ZYNLONTA in combination with rituximab to treat r/r follicular lymphoma (FL) and ZYNLONTA as a monotherapy to treat marginal zone lymphoma (MZL) are ongoing. The Company anticipates publication of data from both IITs between the end of 2026 and mid-2027.
More news about: ADC Therapeutics SA
May 01, 2026, 04:05 ET ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.Headquartered
More news about: ADC Therapeutics SA
Apr 29, 2026, 08:05 ET Aflac recognizes 6 leaders as Check for Cancer Champions
information.About the Check for Cancer Champions:Ernie Johnson Jr. is a two-time cancer survivor who has overcome non-Hodgkin's lymphoma and prostate cancer. He credits early detection as a key part of his recovery and has used his platform to advocate for regular cancer screenings,
More news about: Aflac
Apr 29, 2026, 08:00 ET Citius Oncology Ships First International Order of LYMPHIR™ to Europe
the U.S. Food and Drug Administration in August 2024 for the treatment of adult patients with Stage I–III relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy, and was commercially launched in the United States in December 2025.LYMPHIR does not have
More news about: Citius Oncology, Inc.
Apr 28, 2026, 10:54 ET Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution
succinate capsules (SAF-189), Fosun Pharma's Class 1 innovative drug, was accepted by the NMPA, intended for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), expected to provide a new option for precision treatment
More news about: Fosun Pharma
Apr 28, 2026, 08:00 ET AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata
immune system problems. RINVOQ may increase your risk of certain cancers. Lymphoma and other cancers, including skin cancers, can happen. Current or past smokers are at higher risk of certain cancers, including lymphoma and lung cancer. Follow your HCP's advice about having your skin checked for skin
More news about: AbbVie
Apr 28, 2026, 07:30 ET Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
the University of Pennsylvania that was a leading enroller in the Phase 3 FLASH study.About Cutaneous T-Cell Lymphoma (CTCL)CTCL is a class of non-Hodgkin's lymphoma (NHL), a type of cancer of the white blood cells that are an integral part of the immune system. Unlike most NHLs which
More news about: SOLIGENIX, INC.
Apr 27, 2026, 16:09 ET Center for Food Safety Leads Movement for Science-Based Advocacy Against Industrial Agriculture
ruled that Monsanto failed to warn people that Roundup could cause cancer, and that the herbicide was a major factor leading to their non-Hodgkin lymphoma (NHL). Approximately
More news about: The Center For Food Safety
Apr 27, 2026, 10:24 ET In HelloNation, Radon Mitigation Expert Paul Nicholson Discusses Key Factors in Radon Mitigation Systems
pressurize through the foundation floor. Prolonged exposure to elevated radon levels has been linked to lung cancer, and is suspected in Leukemia and Lymphoma cases. Because radon cannot be detected without testing, homeowners must rely on proper measurement and mitigation to ensure safety.Radon mitigation
More news about: HelloNation
Apr 27, 2026, 07:55 ET Xcovery Partners with EVERSANA to Commercialize Lung Cancer Drug Ensacove in the U.S.
industry, to support and expand the U.S. commercial launch of ENSACOVE™ (ensartinib), the company's novel therapy for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
More news about: EVERSANA
Apr 27, 2026, 07:30 ET ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026
accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.Headquartered
More news about: ADC Therapeutics SA